The P16, coded by CDKN2A/CDKN2B, was a main inhibitor of CDK4/CDK6; therefore, high deletion rate of CDKN2A/CDKN2B in GBM indicated that CDK4/CDK6 might be highly activated. Here, CDK4 is linked to glioblastoma.